Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications
Fatma Haddad, Ghadeer Dokmak, Maryam Bader, et al.
Life (2023) Vol. 13, Iss. 4, pp. 1012-1012
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Association of semaglutide with risk of suicidal ideation in a real-world cohort
William Wang, Nora D. Volkow, Nathan A. Berger, et al.
Nature Medicine (2024) Vol. 30, Iss. 1, pp. 168-176
Open Access | Times Cited: 102
Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset
Stefania Chiappini, Rachel Vickers‐Smith, Daniel R. Harris, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 7, pp. 994-994
Open Access | Times Cited: 34
Advances in incretin therapies for targeting cardiovascular disease in diabetes
Theresa L. Roberts, Dana S. Hutchinson, Denise Wootten, et al.
Journal of Molecular and Cellular Cardiology (2025)
Closed Access
Trends in cardiometabolic risk factors according to body mass index in Peru between 2015 and 2023
Rodrigo M. Carrillo‐Larco, Antonio Bernabé‐Ortiz
Annals of Epidemiology (2025)
Closed Access
Isolation and identification of a novel bisacodyl analogue, bisacodyl dicycloproyl carboxylate, as a potential illegal additive in a dried plum product advertised for weight loss
Xianxian Li, Feng Jiang, Hong Yu, et al.
Food Additives & Contaminants Part A (2025), pp. 1-8
Closed Access
Alterations of the gut microbiota and metabolites by ShenZhu TiaoPi granule alleviates hyperglycemia in GK rats
Jindong Zhao, Zhaohui Fang
Frontiers in Microbiology (2024) Vol. 15
Open Access | Times Cited: 4
The dark side of drug repurposing. From clinical trial challenges to antimicrobial resistance: analysis based on three major fields
Iyad Natsheh, Majd M. Alsaleh, Ahmad Khalaf Alkhawaldeh, et al.
Drug Target Insights (2024) Vol. 18, Iss. 1, pp. 8-19
Open Access | Times Cited: 3
Glucagon‐like‐peptide‐1 receptor agonists versus dipeptidyl peptidase‐4 inhibitors and cardiovascular outcomes in diabetes in relation to achieved glycemic control. A Danish nationwide study
Bochra Zareini, Kathrine Kold Sørensen, Ulrik Pedersen‐Bjergaard, et al.
Journal of Diabetes (2024) Vol. 16, Iss. 6
Open Access | Times Cited: 2
Recent Developments in 1,2,3‐Triazole Based α‐Glucosidase Inhibitors: Design Strategies, Structure‐Activity Relationship and Mechanistic Insights
Atamjit Singh, Karanvir Singh, Aman Sharma, et al.
Chemistry & Biodiversity (2024) Vol. 21, Iss. 9
Closed Access | Times Cited: 2
Molecular Aspects in the Development of Type 2 Diabetes and Possible Preventive and Complementary Therapies
Laura Simon-Szabó, Beáta Lizák, Gábor Sturm, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 16, pp. 9113-9113
Open Access | Times Cited: 2
Is there a risk for Semaglutide Misuse? Focus on the Food and Drug Administration-FDA Adverse Events Reporting System (FAERS) pharmacovigilance dataset
Stefania Chiappini, Rachel Vickers‐Smith, Duccio Papanti, et al.
(2023)
Open Access | Times Cited: 6
Trajectories of BMI before and after diagnosis of type 2 diabetes in a real-world population
Louise A. Donnelly, Rory J. McCrimmon, Ewan R. Pearson
Diabetologia (2024) Vol. 67, Iss. 10, pp. 2236-2245
Open Access | Times Cited: 1
Dulaglutide (Trulicity)-Induced Acute Pancreatitis: A Case Report
Abu baker Khan, Aimal Shah, Saad Ahmad, et al.
Cureus (2023)
Open Access | Times Cited: 4
The DPP-4 inhibitor sitagliptin improves glycaemic control and early-stage diabetic nephropathy in adolescents with type 1 diabetes using the MiniMed 780G advanced hybrid closed-loop system: a randomised controlled trial
Nancy Samir Elbarbary, Eman Abdel Rahman Ismail, Manal El‐Hamamsy, et al.
Diabetologia (2024)
Open Access | Times Cited: 1
The impact of vildagliptin as an add‐on therapy on matrix metalloproteinase‐14 levels, liver stiffness and subclinical atherosclerosis in adolescents with type 1 diabetes and non‐alcoholic steatohepatitis: A randomized controlled trial
Zeinab A. El-Kabbany, Eman Abdel Rahman Ismail, Eman Tawfik Hamed, et al.
Diabetes Obesity and Metabolism (2024)
Closed Access | Times Cited: 1
RGB Trichromatic Whiteness Assessment of Bio Analytical Chromatographic Tool Using Fluorescence for Quantitation of Semaglutide: Application to Pharmaceutical Preparations and Spiked Plasma
Mona M. Abdel Moneim, Miranda F. Kamal, Mohamed M. A. Hamdy
Journal of Fluorescence (2024)
Open Access | Times Cited: 1
Knowledge, attitudes, and practices towards the use of GLP-1 receptor agonists for weight loss among the general population in Jordan; A cross-sectional study
Rana Abutaima, Muna Barakat, Hana M. Sawan, et al.
PLoS ONE (2024) Vol. 19, Iss. 12, pp. e0314407-e0314407
Open Access | Times Cited: 1
A Semaglutida aplicada ao tratamento da obesidade: perspectivas clínicas na literatura
Maria Carolina Alves Zanatta, Fabiana Sambini da Rocha, Tarcísia Alves Sambini Fumagali, et al.
Research Society and Development (2023) Vol. 12, Iss. 9, pp. e10012943295-e10012943295
Open Access | Times Cited: 3
The Effects of Sodium–Glucose Cotransporter 2 Inhibitors on Body Composition in Type 2 Diabetes Mellitus: A Narrative Review
Soodeh Jahangiri, Mojtaba Malek, Sanjay Kalra, et al.
Diabetes Therapy (2023) Vol. 14, Iss. 12, pp. 2015-2030
Open Access | Times Cited: 3
O USO DA SEMAGLUTIDA NO TRATAMENTO DE OBESIDADE E DIABETES MELLITUS TIPO 2
Luiza Braga Cabrera, Lara Caroline Pateis da Silva, Sérgio dos Santos Camargo, et al.
Revista Ibero-Americana de Humanidades, Ciências e Educação (2023) Vol. 9, Iss. 10, pp. 25-38
Open Access | Times Cited: 2
Semaglutide+Reduces+Overconsumption+of+HFD+in+a+Rodent+Model+of+Binge+Eating
Jamila Guard
(2024)
Open Access
PERIGOS E CONSEQUÊNCIAS DO USO INDISCRIMINADO DE OZEMPIC NO EMAGRECIMENTO
Thaynara Paula Warren Bezerra, Pedro César de Souza, Paulo André Teixeira de Morais Gomes, et al.
Revista Foco (2024) Vol. 17, Iss. 6, pp. e5289-e5289
Open Access
Sustained Long-Term Significant Weight Reduction by Empagliflozin in an Adult Female Patient
Neeraj Sinha
International Journal of Diabetes and Technology (2024) Vol. 3, Iss. 1, pp. 32-34
Closed Access
The Obese Brain
Sara Carmo‐Silva, Clévio Nóbrega
Obesity (2024), pp. 9-37
Closed Access
Causal relationships between GLP1 receptor agonists, blood lipids, and heart failure: a drug-target mendelian randomization and mediation analysis
Tianshi Mao, Jie Chen, Tong Su, et al.
Diabetology & Metabolic Syndrome (2024) Vol. 16, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top